NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Large Growth in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 230,100 shares, a growth of 42.7% from the January 31st total of 161,300 shares. Based on an average daily volume of 273,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 16th.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock traded up $0.05 during trading hours on Tuesday, hitting $1.10. 182,710 shares of the company were exchanged, compared to its average volume of 247,411. The firm has a market cap of $15.03 million, a P/E ratio of -1.72 and a beta of 1.27. NeuroSense Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.25. The company has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $1.12.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) EPS for the quarter.

Institutional Trading of NeuroSense Therapeutics

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd grew its position in shares of NeuroSense Therapeutics by 40.9% during the 3rd quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock worth $58,000 after buying an additional 13,346 shares during the period. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics in the 4th quarter worth $78,000. Finally, Citadel Advisors LLC lifted its holdings in shares of NeuroSense Therapeutics by 640.9% in the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock worth $305,000 after purchasing an additional 219,717 shares in the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.